Curriculum

CURRICULUM

COSENZA LUCIA CARMELA

CURRENT POSITION:
Technical Administrative Staff, Officer Category D, at the Department of Translational Medicine and for Romagna, University of Ferrara.

EDUCATIONAL QUALIFICATIONS:

  • 16-07-2008: Bachelor's Degree in Interfaculty Biotechnology, University of Ferrara
  • 18-10-2010: Master's Degree in Medical-Pharmaceutical Biotechnology (9/S), University of Ferrara
  • 27-03-2015: PhD in Biochemistry, Molecular Biology, and Biotechnology, University of Ferrara

PROFESSIONAL POSITIONS AND WORK EXPERIENCE:

  • 01-07-2015 / 30-06-2016: Research grant for research activities. Scientific sector BIO-10. Title: Production of fetal hemoglobin in blood transfused subjects (WADA- Research Grant N.14C06FM). Department of Life Sciences and Biotechnology, University of Ferrara.
  • 01-06-2017 / 31-10-2017: Research grant. Title: Development of cell biobanks in the context of thalassemia. Department of Life Sciences and Biotechnology, University of Ferrara.
  • 01-03-2018 / 30-06-2018: Occasional collaboration contract for RARE-Partners S.r.l. (social enterprise, Corso Magenta 31 - 20121 – Milan). Title: Preparation of documentation for setting up a cell biobank aimed at phenotypic and genotypic characterization of patients affected by hemoglobinopathies.
  • 01-05-2018 / 02-02-2024: Research grant for research activities. Scientific sector BIO-10. Title: Development, validation, and maintenance of a cell biobank for hemoglobinopathies (CUP F73C16000000005). Department of Life Sciences and Biotechnology, University of Ferrara.

TEACHING ACTIVITIES
Teaching Assignments:

  • MOLECULAR AND RECOMBINANT TECHNOLOGIES module of the course "Biochemical and Recombinant Technologies" in the Bachelor's program in Biotechnology, Health and Environment track.
  • OMICS AND MOLECULAR DIAGNOSTICS for the Master's program in Biotechnology for Health and Environment. Department of SVEB, University of Ferrara.

Teaching Support and Seminars:

  • CELLULAR AND MOLECULAR THERAPIES related to the "Biotechnological Drugs" course in the Bachelor's degree in Biotechnology, Health track.
  • OMICS AND MOLECULAR DIAGNOSTICS for the Master's degree in Biotechnology for Health and Environment.
  • MOLECULAR AND RECOMBINANT TECHNOLOGIES in the Bachelor's degree in Biotechnology, Health and Environment tracks.

Subject Expert:

  • Molecular and Recombinant Technologies (SSD BIO/11).
  • Cellular and Molecular Therapies (SSD BIO/10).
  • Omics and Molecular Diagnostics (SSD BIO/10).

SCIENTIFIC ACTIVITIES

Research Projects:

  • Project Title: The read-through approach for the treatment of cystic fibrosis caused by premature termination codons: FFC Grant Application #1- 2012. Duration: September 1, 2012 - August 31, 2014. Role: Internal collaborator.
  • Project Title: EU FP7 THALAMOSS (THalassemia MOdular Stratification System) Project grant n.306201-FP7-Health-2012-INNOVATION-1. Duration: November 1, 2012 - April 30, 2017. Role: Internal collaborator.
  • Project Title: Characterization and use of mouse models for thalassemia. Ministerial Authorization for Animal Experimentation issued on 11-05-2015, expiring on 11-05-2020. Role: Internal collaborator.
  • Project Title: Production of fetal hemoglobin in blood transfused subjects. Novel molecular biomarkers for the detection of autologous blood transfusion in sport: fetal hemoglobin and microRNA WADA1 (World Anti-Doping Agency) – Research Grant N. 14C06FM. Duration: 2015-2016. Role: Internal collaborator.
  • Project Title: Development of microRNA-based protocols for detection of autologous blood transfusion in sport WADA2 (World Anti-Doping Agency) – Research Grant N. 14C06FM. Duration: 06-04-2018/05-04-2019. Role: Internal collaborator.
  • Wellcome Trust Project Title: Fetal hemoglobin (HbF) induction as a strategy to improve quality of life in Thalassemia: characterization of HbF inducing products and preclinical models to predict therapeutic response. (ID GRANT: 104744). Duration: 01/11/2014. Role: Internal collaborator.
  • Wellcome Trust Project 2017/28-02-2020 (extension 28-02-2022): “A personalized medicine approach for beta-thalassemia patients: testing sirolimus in a first pilot clinical trial (Sirthalaclin). CLINICALTRIALS.GOV IDENTIFIER: NCT03877809. Role: Internal collaborator.
  • Project Title: Multi-task evaluation of TMA analogues as anti-inflammatory treatments for CF lung disease: FFC Grant Application #22/2019. Duration: September 1, 2019 - November 30, 2020. Role: Internal collaborator.
  • AIFA Project 2016-2021: "Treatment of Beta-Thalassemia patients with Rapamycin (Sirolimus): from pre-clinical research to a clinical trial." (ThalaRap). CLINICALTRIALS.GOV IDENTIFIER: NCT04247750. Amendment 2023. Role: Internal collaborator.
  • Project SDS: Combined approaches for Shwachman-Diamond Syndrome: microRNA targeting, gene editing, and read-through correction (miRCOMBO-SDS). Shwachman-Diamond Syndrome Italian Research Grant 2020-2021. Role: Internal collaborator.
  • Project Title: GY971 as anti-inflammatory agent 2.0: FFC Grant Application 2024 Duration: 2 years. Role: Internal collaborator.

Participation in Research Groups:

  • FAR 2012 Project: "Study and modulation of gene expression with oligonucleotides, PNA, and therapeutic vectors." Principal Investigator: Prof. Roberto Gambari. Role: Internal collaborator. 03/06/2013-03/06/2016.
  • FAR 2013 Project: "Study and modulation of gene expression with oligonucleotides, PNA, and therapeutic vectors." Principal Investigator: Prof. Roberto Gambari. Role: Internal collaborator. 12/05/2014-12/05/2017.
  • FAR 2014 Project: "Study and modulation of gene expression with oligonucleotides, PNA, and therapeutic vectors." Principal Investigator: Prof. Roberto Gambari. Role: Internal collaborator. 01/07/2015-30/06/2018.

Main Research Areas:

  • Gene editing (CRISPR/Cas9) on CD34+ cells and ErPCs isolated from thalassemia patients for correction of mutations in the beta-globin gene, and genomic analysis through NGS whole genome and amplicons to evaluate effects of donor template insertion and deletions induced by Cas9 enzyme cutting.
  • Combined treatments associated with HbF induction.
  • Gene editing (CRISPR/Cas9) and tcPNA for the correction of point mutations in ErPCs and hematopoietic stem cells CD34+ isolated from thalassemia patients and other cellular models.
  • Identification of circulating microRNAs in the plasma of athletes undergoing autologous blood transfusion (a method usable in anti-doping).
  • Isolation of CD34+ cells and culture of erythroid precursors with the creation of a cell biobank from beta-thalassemia patients for gene therapy experiments using lentiviral vectors or gene editing techniques.
  • Study of new fetal hemoglobin inducers in beta-thalassemia and sickle cell anemia.
  • Production, screening, and validation of mouse models for in vivo study of some of the most frequent mutations for beta-thalassemia in Italy.
  • Study of new polymorphisms related to increased HbF.
  • Production of cellular sensors for high throughput screening of read-through active molecules.
  • Study of read-through active molecules in cystic fibrosis and β-thalassemia.
  • Application of various molecular biology methods (Real-time PCR, ddPCR, Surface Plasmon Resonance - BIACORE) for non-invasive prenatal diagnosis of beta-thalassemia based on Sanger sequencing.
  • MicroRNA expression analysis in colon cancer.

AWARDS AND RECOGNITIONS:

  • Paolo Bianco Award VII° Stem Cell Research for the poster: 'A validated THALAMOSS cellular biobank for gene therapy studies and iPS generation'. Istituto Ortopedico Rizzoli, Bologna. June 21-23, 2016.

SCIENTIFIC PRODUCTION
Author of 37 articles published in peer-reviewed international journals. Bibliographic indices in Scopus: h-index 13.

Scopus Author ID: 56652103500 ORCID 0000-0002-2949-7191

 

  1. Gambari R, Gamberini MR, Cosenza LC, Zuccato C, Finotti A. A β-Thalassemia Cell Biobank: Updates, Further Validation in Genetic and Therapeutic Research and Opportunities During (and After) the COVID-19 Pandemic. J Clin Med. 2025 Jan 6;14(1):289. doi: 10.3390/jcm14010289. PMID: 39797371; PMCID: PMC11722022
  2. Zurlo, M.; Zuccato, C.; Cosenza, L.C.; Gamberini, M.R.; Finotti, A.; Gambari, R. Increased Expression of α-Hemoglobin Stabilizing Protein (AHSP) mRNA in Erythroid Precursor Cells Isolated from β-Thalassemia Patients Treated with Sirolimus (Rapamycin). J. Clin. Med. 2024, 13, 2479. https://doi.org/10.3390/jcm13092479
  3. Lucia Carmela Cosenza 1, Giovanni Marzaro 2, Matteo Zurlo 1, Jessica Gasparello 1, Cristina Zuccato 1 3, Alessia Finotti 1 3, Roberto Gambari Inhibitory effects of SARS-CoV-2 Spike protein and BNT162b2 vaccine on erythropoietin-induced globin gene expression in erythroid precursor      cells                              (ErPCs)         from                    β-thalassemia patients. https://doi.org/10.1016/j.exphem.2023.11.002
  4. Zurlo M, Gasparello J, Verona M, Papi C, Cosenza LC, Finotti A, Marzaro G, Gambari R. The anti-SARS-CoV-2 BNT162b2 vaccine suppresses mithramycin-induced erythroid differentiation and expression of embryo-fetal globin genes in human erythroleukemia K562 cells. Exp Cell Res. 2023 Dec 15;433(2):113853. doi: 10.1016/j.yexcr.2023.113853. Epub 2023 Nov 7. PMID: 37944576.
  5. Zurlo M, Zuccato C, Cosenza LC, Gasparello J, Gamberini MR, Stievano A, Fortini M, Prosdocimi M, Finotti A, Gambari R. Decrease in α-Globin and Increase in the Autophagy- Activating Kinase ULK1 mRNA in Erythroid Precursors from β-Thalassemia Patients Treated with Sirolimus. International Journal of Molecular Sciences. 2023; 24(20):15049. https://doi.org/10.3390/ijms242015049
  6. Cristina  Zuccato,  Lucia  Carmela  Cosenza,  Chiara  Tupini,  Alessia Finotti, Gianni Sacchetti, Daniele Simoni, Roberto Gambari *, Ilaria Lampronti. New Synthetic  Isoxazole  Derivatives  acting  as  potent  Inducers  of  Fetal Hemoglobin in Erythroid Precursor Cells isolated from b-Thalassemic Patients. Molecules Manuscript ID: molecules-2745646
  7. Finotti, A.; Gasparello, J.; Zuccato, C.; Cosenza, L.C.; Fabbri, E.; Bianchi, N.; Gambari, R. Effects of Mithramycin on BCL11A Gene Expression and on the Interaction of the BCL11A Transcriptional Complex to γ-Globin Gene Promoter Sequences. Genes 2023, 14, 1927. https://doi.org/10.3390/genes14101927
  8. Maria Rita Gamberini *, Cristina Zuccato, Matteo Zurlo, Lucia Carmela Cosenza, Alessia Finotti *, Roberto Gambari. Effects of Sirolimus Treatment on fetal hemoglobin production andn response to SARS-CoV-2 Vaccination: a Case Report Study. Hematology Reports Manuscript ID: hematolrep-2404523 Type of manuscript: Case Report . Hematol Rep. 2023 Jul 12;15(3):432-439. doi: 10.3390/hematolrep15030044. PMID: 37489374; PMCID: PMC10366771.
  9. Gambari R, Zuccato C, Cosenza LC, Zurlo M, Gasparello J, Finotti A, Gamberini MR, Prosdocimi M. The Long Scientific Journey of Sirolimus (Rapamycin): From the Soil of Easter Island (Rapa Nui) to Applied Research and Clinical Trials on β-Thalassemia and Other Hemoglobinopathies. Biology (Basel). 2023 Sep 2;12(9):1202. doi: 10.3390/biology12091202. PMID: 37759601; PMCID: PMC10525103.
  10. 10. Chiara   Papi,   Jessica   Gasparello,   Matteo   Zurlo,   Lucia   Carmela Cosenza, Roberto Gambari *, Alessia Finotti *The Cystic Fibrosis Transmembrane Conductance                                           Regulator                       Gene                      (CFTR)                       is under post-transcriptional control of microRNAs: analysis of the effects of agomiRNAs mimicking miR-145-5p, miR-101-3p and miR-335-5p. Noncoding RNA. 2023 Apr 18;9(2):29. doi: 10.3390/ncrna9020029. PMID: 37104011; PMCID: PMC10146138.
  11. Zurlo, M.; Gasparello, J.; Cosenza, L.C.; Breveglieri, G.; Papi, C.; Zuccato, C.; Gambari, R.; Finotti, A. Production and Characterization of K562 Cellular Clones Hyper-Expressing the Gene Encoding α-Globin: Preliminary Analysis of Biomarkers Associated with Autophagy. Genes 2023, 14, 556. https://doi.org/10.3390/genes14030556
  12. Zuccato C, Cosenza LC, et al. The rs368698783 (G>A) Polymorphism Affecting LYAR Binding to the Aγ-Globin Gene Is Associated with High Fetal Hemoglobin (HbF) in β- Thalassemia Erythroid Precursor Cells Treated with HbF Inducers. Int J Mol Sci. 2023 Jan 1;24(1):776. doi: 10.3390/ijms24010776. PMID: 36614221.
  13. Zurlo M, Nicoli F, et al. Effects of Sirolimus treatment on patients with β-Thalassemia: Lymphocyte immunophenotype and biological activity of memory CD4+ and CD8+ T cells. J Cell Mol Med. 2023 Jan 10. doi: 10.1111/jcmm.17655. Epub ahead of print. PMID: 36625233.
  14. Tupini C, Chilin A. et al. New TMA (4,6,4'-Trimethyl angelicin) Analogues as Anti- Inflammatory Agents in the Treatment of Cystic Fibrosis Lung Disease. Int J Mol Sci. 2022 Nov 21;23(22):14483. doi: 10.3390/ijms232214483. PMID: 36430961; PMCID: PMC9699093.
  15. Lucia Carmela Cosenza*, Cristina Zuccato, Matteo Zurlo , Roberto Gambari ,* and Alessia Finotti. Co‐Treatment of Erythroid Cells from β‐Thalassemia Patients with CRISPR‐Cas9‐ Based β039‐Globin Gene Editing and Induction of Fetal Hemoglobin Genes 2022, 13, 1727. https://doi.org/10.3390/genes13101727
  16. Marco Prosdocimi, Cristina Zuccato, Lucia Carmela Cosenza, Monica Borgatti, Ilaria Lampronti, Alessia Finotti, Roberto Gambari. A Rational Approach to Drug Repositioning in β-thalassemia: Induction of Fetal Hemoglobin by Established Drugs. Wellcome Open Research 2022, 7:150 Last updated: 12 MAY 2022.
  17. Zuccato C*, Cosenza LC*, Zurlo M, Gasparello J, Papi C, D'Aversa E, Breveglieri G, Lampronti I, Finotti A, Borgatti M, Scapoli C, Stievano A, Fortini M, Ramazzotti E, Marchetti N, Prosdocimi M, Gamberini MR, Gambari R. Expression of γ-globin genes in β-thalassemia patients treated with sirolimus: results from a pilot clinical trial (Sirthalaclin). Ther Adv Hematol. 2022 Jun 21;13:20406207221100648. doi: 10.1177/20406207221100648. PMID: 35755297; PMCID: PMC9218916.
  18. Gasparello J, Papi C, et al. Teaching during COVID-19 pandemic in practical laboratory classes of applied biochemistry and pharmacology: A validated fast and simple protocol for detection of SARS-CoV-2 Spike sequences. PLoS One. 2022 Apr 6;17(4):e0266419. doi: 10.1371/journal.pone.0266419. PMID: 35385518; PMCID: PMC8985952.
  19. Zuccato C, Cosenza LC, Zurlo M, Lampronti I, Borgatti M, Scapoli C, Gambari R, Finotti A. Treatment of Erythroid Precursor Cells from β-Thalassemia Patients with Cinchona Alkaloids: Induction of Fetal Hemoglobin Production. Int J Mol Sci. 2021 Dec 14;22(24):13433. doi: 10.3390/ijms222413433. PMID: 34948226; PMCID: PMC8706579.
  20. Lucia Carmela Cosenza*, Jessica Gasparello, Nicola Romanini, Matteo Zurlo, Cristina Zuccato, Roberto Gambari, Alessia Finotti. Efficient CRISPR/Cas9 based genome editing of β-globin gene on erythroid cells from homozygous β039-thalassemia patients -Mol Ther Methods Clin Dev. 2021 Apr 3;21:507-523. doi: 10.1016/j.omtm.2021.03.025. PMID: 33997100; PMCID: PMC8091488.
  21. Nanou A, Toumpeki C, Fanis P, Bianchi N, Cosenza LC, Zuccato C, Sentis G, Giagkas G, Stephanou C, Phylactides M, Christou S, Hadjigavriel M, Sitarou M, Lederer CW, Gambari R, Kleanthous M, Katsantoni E. Sex-specific transcriptional profiles identified in β- thalassemia patients. Haematologica. 2021 Apr 1;106(4):1207-1211. doi: 10.3324/haematol.2020.248013. PMID: 32817281; PMCID: PMC8018115.
  22. Giulia Breveglieri, Salvatore Pacifico, Cristina Zuccato, Lucia Carmela Cosenza, Shaiq Sultan, Elisabetta D'Aversa, Roberto Gambari, Delia Preti, Claudio Trapella, Remo Guerrini *, Monica Borgatti * Discovery of novel fetal hemoglobin inducers for β-thalassemia by small chemical library screening. Received: 4 June 2020. ID: ijms-841863.
  23. Giulia Breveglieri, Elisabetta D’Aversa, Lucia Carmela Cosenza, Effrossyni Boutou et al. Detection of the sickle hemoglobin allele using a surface plasmon resonance based biosensor. Sensors and Actuators B: Chemical. Elsivier. https://doi.org/10.1016/j.snb.2019.05.081
  24. Breveglieri G, Salvatori F, Finotti A, Cosenza LC et al. Development and characterization of cellular biosensors for HTS of erythroid differentiation inducers targeting the transcriptional activity of γ-globin and β-globin gene promoters. Anal Bioanal Chem. 2019 Jul 4. doi: 10.1007/s00216-019-01959-z
  25. Gasparello J, Lamberti N, Papi C, Lampronti I, Cosenza LC, Fabbri E, Bianchi N, Zambon C, Dalla Corte F, Govoni M, Reverberi M, Manfredini F, Gambari R, Finotti A. Altered erythroid- related miRNA levels as a possible novel biomarker for detection of autologous blood transfusion misuse in sport. Transfusion. 2019.
  26. Milani R, Brognara E, Fabbri E, Manicardi A, Corradini R, Finotti A, Gasparello J, Borgatti M, Cosenza LC, lampronti I, Dechecchi MC, Cabrini G. Targeting miR-155-5p and miR-221- 3p by Peptide Nucleic Acids (PNAs): Induction of Caspase-3 and Apoptosis in Temozolomide- Resistant T98G glioma cells. Int J Oncol. 2019.
  27. Gemmo C, Breveglieri G, Marzaro G, Lampronti I, Cosenza LC, Gasparello J, Zuccato C, Fabbri E, Borgatti M, Chilin A, Finotti A, Gambari R. Surface Plasmon Resonance (SPR)- based analysis of the binding of LYAR protein to the rs368698783 (G >A) polymorphic Aγ- globin gene sequences mutated in β-thalassemia. Analytical and Bioanalytical Chemistry, 2019;
  28. Nicola Lamberti; Alessia Finotti; Jessica Gasparello; Ilaria Lampronti; Christel Zambon; Lucia Carmela Cosenza; Enrica Fabbri; Nicoletta Bianchi; Francesca Dalla Corte; Maurizio Govoni; Roberto Reverberi; Roberto Gambari; Fabio Manfredini. "Changes in hemoglobin profile reflect autologous blood transfusion misuse in sports" (IAEM-D-18-00078R1). Internal and Emergency Medicine https://doi.org/10.1007/s11739-018-1837-7
  29. Giulia Breveglieri; Elisabetta D'Aversa; Tiziana Eleonora Gallo; Patrizia Pellegatti; Giovanni Guerra; Lucia Carmela Cosenza; Alessia Finotti; Roberto Gambari; Monica Borgatti. A novel and efficient protocol for surface plasmon resonance based detection of four β-thalassemia point mutations in blood samples and salivary swabs. Elsevier Sensors and Actuators B: Chemical .Volume 260, 1 May 2018, Pages 710-718 doi.org/10.1016/j.snb.2017.12.209
  30. Finotti A, Gasparello J, Lampronti I, Cosenza LC, Maconi G, Matarese V, Gentili V, Di Luca D, Gambari R, Caselli M. PCR detection of segmented filamentous bacteria in the terminal ileum of patients with ulcerative colitis. BMJ Open Gastroenterol. 2017 Dec 4;4(1):e000172. doi: 10.1136/bmjgast-2017-000172. eCollection 2017
  31. Breveglieri G, Bianchi N, Cosenza LC, Gamberini MR, Chiavilli F, Zuccato C, Montagner G, Borgatti M, Lampronti I, Finotti A, Gambari R. An Aγ-globin G->A gene polymorphism associated with β039 thalassemia globin gene and high fetal hemoglobin production. BMC Med Genet. 2017 Aug 29;18(1):93. doi: 10.1186/s12881-017-0450-3
  32. Breveglieri G, Travan A, D'Aversa E, Cosenza LC, Pellegatti P, Guerra G, Gambari R, Borgatti M. Postnatal and non-invasive prenatal detection of β- thalassemia mutations based on Taqman genotyping assays.( PLoS One. 2017 Feb 24;12(2): e0172756. doi: 10.1371/journal.pone.0172756. eCollection 2017)
  33. Lucia Carmela Cosenza*, Laura Breda, Giulia Breveglieri, Cristina Zuccato, Alessia Finotti, Ilaria Lampronti, Monica Borgatti, Francesco Chiavilli, Maria Rita Gamberini, Stefania Satta, Paolo Moi, Stefano Rivella, Roberto Gambari and Nicoletta Bianchi. A validated cellular Biobank for β-Thalassemia (J Transl Med. 2016 Sep 2;14(1):255) PMID: 27590532 DOI: 10.1186/s12967-016-1016-4
  34. Bianchi N, Cosenza LC, Lampronti I, Finotti A, Breveglieri G, Zuccato C, Fabbri E, Marzaro G, Chilin A, De Angelis G, Borgatti M, Gallucci C, Alfieri C, Ribersani M, Isgrò A, Marziali M, Gaziev J, Morrone A, Sodani P, Lucarelli G, Gambari R, Paciaroni K. Structural and functional insights on an uncharacterized Aγ-globin gene polymorphism present in four β0- thalassemia families with high fetal hemoglobin levels. (Mol Diagn Ther. 2016 Apr;20(2):16173. doi: 10.1007/s40291-016-0187-2
  35. G. Breveglieri, E. Bassi, S. Carlassara, L.C. Cosenza, P. Pellegatti, G. Guerra, A. Finotti, R. Gambari, and M. Borgatti. Y-chromosome identification in circulating cell-free fetal DNA using surface plasmon. Prenat Diagn. 2016 Feb 5. doi: 10.1002/pd.4788
  36. Breveglieri G., Mancini I., Bianchi N., Lampronti I., Salvatori F., Fabbri E, Zuccato C, Cosenza L. C., Montagner G., Borgatti M., Altruda F., Fagoonee S., Carandina G., Rubini M., Aiello V., Breda L., Rivella S., Gambari R., Finotti A. Generation and characterization of a transgenic mouse carrying a functional human beta-globin gene with the IVSI-6 thalassemia mutation. BioMed Research InternationalBioMed Research International, vol. 2015, Article ID 687635, 20 pages, 2015.
  37. Alessia Finotti, Jessica Gasparello, Giulia Breveglieri, Lucia Carmela Cosenza, Alberto Bresciani, Sergio Altamura, Nicoletta Bianchi, Elisa Martini, Monica Borgatti and Roberto Gambari. Development and characterization of K562 cell clones expressing BCL11A-XL: decreased hemoglobin production with fetal hemoglobin inducers and its rescue with mithramycin. Exp Hematol. 2015 Dec; 43(12):1062-1071.e3. doi: 10.1016/j.exphem.2015.08.011. Epub 2015 Sep 3

 

Reviewer for Journals:

  • Member of the journal Frontiers: May 13, 2023 – Present. Role: Review Editor in Molecular Diagnostics and Therapeutics.

  • Reviewer for Thalassemia Reports, Journal of Clinical Medicine: "Impact of Genetic Polymorphisms in Modifier Genes in Determining Fetal Hemoglobin Levels in Beta-Thalassemia."

  • Reviewer for Scientific Reports. Article: "Hsa_circ_0129875 combined with mean corpuscular volume and mean corpuscular hemoglobin improves the sensitivity and specificity of the diagnosis of thalassemia."

  • Reviewer for the MDPI editorial group, journal Journal of Clinical Medicine. Article: "Genome editing for β-hemoglobinopathies: advances and challenges." Authors of the review: Giacomo Frati, Annarita Miccio.